ArticleHeliyon2025
Chestnut (
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chromium(III) Beyond Insulin: A Mechanistic Roadmap Across the Energy-Redox-Inflammation Triad in Obesity and Cardiometabolic Disease.Biological trace element research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A by-product is a secondary substance unintentionally produced during manufacturing and can be repurposed through recycling. In particular, by-products generated from the processing of natural materials are valuable because of their bioactive compound content, such as polyphenols and anthocyanins. Obesity is a global health issue, and medicines for obesity have side effects, such as insomnia and headaches. The demand for safe anti-obesity treatments based on natural products has increased. In this study, the anti-obesity efficacy of chestnut inner skin powder (CIS), a by-product, was investigated in a high-fat diet (HFD)-induced obesity model. CIS (100, 500, and 1000 mg/kg) was administered orally for 7 weeks, and 200 mg/kg garcinia was used as the positive control. Body weight (BW) and food intake were monitored weekly. Our results showed that CIS intake reduced BW, liver weight, white adipose tissue (WAT) weight (epididymal, retroperitoneal, and perirenal tissues), leptin levels, LDL-c levels, and expression of adipogenesis- and lipogenesis-related genes, similar to the positive control group. Additionally, CIS activated the AMPK/ACC signaling pathway in the liver and reduced adipocyte size in the WAT H&E stain. In conclusion, these findings suggest that CIS may prevent and treat obesity by regulating adipogenesis, lipogenesis, and lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.